Saquinavir switch study stopped. Clearinghouse, AIDS Newsletter Database, P.O. Box 6003, Rockville, MD 20849-6003. 800-458-5231 ext. 5714. A fee will apply. NLM AIDSLINE Important note: Information in this article was accurate in 1997. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Saquinavir switch study stopped. Clearinghouse, AIDS Newsletter Database, P.O. Box 6003, Rockville, MD 20849-6003. 800-458-5231 ext. 5714. A fee will apply.

Treat Rev. 1997 Apr;(No 24):6. Unique Identifier : AIDSLINE AIDS/97702573

Abstract: ACTG 333 has been discontinued. Early test results showed that people who took the hard-gel version of saquinavir received no benefit from switching to a new saquinavir formulation, or to indinavir. This suggests that patients who take saquinavir as their first protease inhibitor may not benefit from switching to other protease inhibitors.
Keywords: *Clinical Trials HIV Infections/*DRUG THERAPY HIV Protease Inhibitors/*ADMINISTRATION & DOSAGE Human Saquinavir/*ADMINISTRATION & DOSAGE United States NEWSLETTER ARTICLEKWDclinicaltrialshivinfections/KWDdrugtherapyhivproteaseinhibitors/KWDadministration&dosagehumansaquinavir/KWDadministration&dosageunitedstatesnewsletterarticle
970830
M9781178

Copyright © 1997 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1997. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1997. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .